review clear beat thank success product launch us
stay neutral rate
celltrion hc cthc host earn call march top
line softer miss op came bn beat
reclaim double-digit opm first time sinc
highlight gpm improv vs
thank improv region mix america given truxima
herzuma shipment us truxima sale disclos
surg yoy ahead direct entri eu
outlook guidanc given ceo hk
confid achiev double-digit opm also guid stronger
product mix remsima iv sc mark highest
follow truxima herzuma reiter premium strategi
remsima sc label expans expect
rais tp appli higher price-to-earnings
histor high earn form mix tp fine-
tune ep line forecast
neutral think stock fairli valu forese
competit risk us/eu limit remsima sc sale
number share mn
chg prev ep
estimate pot chg tp
op surpris met street highest estim
celltrion hc cthc host earn call top line
somewhat softer miss op came bn beat
met number highest estim street
reclaim double-digit opm first time sinc
bloomberg profession servic credit suiss estim
margin expans underway gpm improv vs
thank improv region mix america vs
us truxima shipment continu us herzuma kick
ahead launch seem sale breakdown
region disclos manag state flat qoq growth
us truxima cse bn biggest driver margin
expans sg surg yoy ahead eu direct entri
commiss cost etc impact manag portion
sale labour cost growth kick given new hire
figur celltrion hc estim sale breakdown region margin trend
shipment truxima inflectra new sale launch us herzuma eu
remsima sc estim bn op opm vs bbg
bn opm product mix remsima iv sc
mark highest follow truxima herzuma accord
ceo
manag commit profit ceo reiter
compani premium strategi remsima sc eu cthc
unwil launch remsima sc price set unfavour
list price germani set per vial
estim remsima sc annual treatment cost rise patient
receiv remsima iv ra uc/cd patient weigh
fuel share price strength bull expect remsima
sc remain rais tp appli higher p/
 histor high earn average form
mix tp dcf fine tune ep
line forecast neutral think
stock fairli valu compar fair valu deriv dcf
upcom downsid risk view remsima sc
forese competit risk us/eu emerg given
launch also find limit
commerci gain remsima sc follow reason
current approv ra-onli rheumatoid arthriti delay
label expans schedul cse jul vs cthc
also requir month regist reimburs
momentum track numer guidanc
given ceo hk confid achiev double-digit opm
cse also guid stronger given on-going us
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
ray certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori celltrion healthcar co ltd
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
charl martineau pm univers toronto credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
